Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Reporting of results to 12.2026 and to 12.2031

Long-term follow-up is necessary to assess the eventual effects of one additional screening on breast cancer incidence, treatment, and, particularly, mortality. As little effect on breast cancer mortality should be expected until years 5-9 and 10-14 after randomisation, prolonged follow-up of mortality will be required, first to the end of 2026 (with the first mortality report due in 2027-28) and then to the end of 2031 (with the final mortality report due in 2032-33).

Follow-up of breast cancer incidence and treatment will be reported in 2025-26, before any unblinded analyses of mortality are reported, but electronic follow-up of breast cancer incidence and treatment will continue after that date. The final report on mortality will be accompanied by updated analyses of breast cancer incidence and treatment, and by health economic analyses.

At least annually, the data monitoring and ethics committee will continue during follow-up to review confidential analyses, particularly of mortality. It can recommend the release of results earlier than scheduled if clear answers emerge.

In this section